NeurAxis, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian Carrico
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11550 North Meridian Street Carmel IN United States of America 46032
- IPO Date
- Aug 9, 2023
- CIK
- 0001933567
- Website
- neuraxis.com
- Similar Companies
- Business
- NeurAxis, Inc. is a medical technology company specializing in the development and commercialization of neuromodulation therapies to treat chronic and debilitating conditions primarily in pediatric and adolescent populations. The company’s core product is IB-Stim, a percutaneous electrical nerve field stimulation (PENFS) device designed as a non-surgical, drug-free solution for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia in patients aged 8 to 21. NeurAxis’s proprietary PENFS technology delivers low-frequency electrical stimulation through cranial nerve branches in the ear to modulate pain-processing centers in the brain. The company targets healthcare providers including hospitals and clinics across the United States. Founded in 2011 and headquartered in Carmel, Indiana, NeurAxis underwent a name change from Innovative Health Solutions, Inc. to its current name in March 2022. Recent major developments include securing a $5 million equity financing round in 2025 to support growth initiatives and commercial expansion. NeurAxis achieved inclusion of its PENFS technology in clinical practice guidelines from leading academic societies, which has positioned IB-Stim as the only FDA-cleared neuromodulation device recommended for pediatric functional abdominal pain. The company also expanded its FDA clearance to include treatment for pediatric functional dyspepsia, broadening its addressable market. Additionally, NeurAxis is advancing national insurance coverage with the forthcoming Category I CPT code utilization beginning January 1, 2026, expected to enhance reimbursement and drive sales growth. These strategic achievements have contributed to strong revenue growth and improved operational efficiency in recent quarters. NeurAxis operates within the healthcare and biotechnology industry, focusing on specialized medical devices. Its mission centers on improving lives by providing safe, effective, evidence-based therapies for children and adolescents suffering from gut-brain interaction disorders. The company’s geographic operations are primarily in the United States, with a focus on advancing adoption of IB-Stim within pediatric gastroenterology treatment settings. As of 2025, NeurAxis maintains a focused product portfolio with an ongoing emphasis on research and innovation in neuromodulation technology to address unmet pediatric healthcare needs. The company is publicly traded on the NYSE American exchange under the ticker NRXS.
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
NeurAxis Expands Payer Coverage with Four New Medical Policies
NeurAxis, Inc. Announces Preferred Stock Dividend
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
NeurAxis (NASDAQ:NRXS) Trading Down 5.7% – Here’s What Happened
The Zacks Analyst Blog Meta, Bank of America, The Procter & Gamble, Espey and NeurAxis
NeurAxis (NASDAQ:NRXS) Stock Price Up 9.6% – Here’s Why
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
NeurAxis, Inc. (NRXS) Q2 2025 Earnings Call Transcript
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
NeurAxis Announces $5.0 Million Registered Direct Offering
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones